Abstract P5-20-14: Cardiotoxicity in 1 year of treatment with reference trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early stage breast cancer (EBC) patients

Autor: Francisco J. Esteva, HC Chung, Sang Joon Lee, Sy Lee, Justin Stebbing, ME Royce

Publikováno v: Cancer Research. 78:P5-20

Background CT-P6 is a proposed biosimilar to reference trastuzumab. This trial (NCT02162667) evaluated the similarity of CT-P6 and reference trastuzumab for both efficacy and safety in HER2 positive EBC patients. The primary endpoint, pathological co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a80b3498e100ab03cf9b35dfcb58d5ce
https://doi.org/10.1158/1538-7445.sabcs17-p5-20-14

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.

Autor: Connolly RM; The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.; Cancer Research at UCC, College of Medicine and Health, University College Cork, Cork, Ireland., Zhao F; Dana-Farber Cancer Institute, Boston, MA., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN., Lee MJ; Center for Cancer Research, National Cancer Institute, Bethesda, MD., Piekarz RL; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Smith KL; The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD., Brown-Glaberman UA; University of New Mexico Cancer Center, Albuquerque, NM., Winn JS; Fox Chase Cancer Center, Philadelphia, PA., Faller BA; Heartland NCORP, Missouri Baptist Medical Centre, Saint Louis, MO., Onitilo AA; Marshfield Clinic, Marshfield, WI., Burkard ME; University of Wisconsin Carbone Cancer Center, Madison, WI., Budd GT; Cleveland Clinic Foundation, Cleveland, OH., Levine EG; Roswell Park Cancer Institute, Buffalo, NY., Royce ME; New Mexico MU-NCORP, Albuquerque, NM., Kaufman PA; University of Vermont Cancer Center, Burlington, VT., Thomas A; Wake Forest University, Winston Salem, NC., Trepel JB; Center for Cancer Research, National Cancer Institute, Bethesda, MD., Wolff AC; The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD., Sparano JA; Montefiore Medical Center, New York, NY.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Oct 01; Vol. 39 (28), pp. 3171-3181. Date of Electronic Publication: 2021 Aug 06.

Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.

Autor: Flores KG; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA. kflores@salud.unm.edu., Steffen LE; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA.; Department of Psychology, University of New Mexico, Albuquerque, NM, USA., McLouth CJ; Department of Psychology, University of New Mexico, Albuquerque, NM, USA., Vicuña BE; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA.; Department of Psychology, University of New Mexico, Albuquerque, NM, USA., Gammon A; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Kohlmann W; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Vigil L; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA., Dayao ZR; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA.; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA., Royce ME; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA.; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA., Kinney AY; University of New Mexico Comprehensive Cancer Center, University of New Mexico, MSC07 4025, 2325 Camino de Salud NE, Albuquerque, NM, 87131-0001, USA.; Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.

Publikováno v: Journal of genetic counseling [J Genet Couns] 2017 Jun; Vol. 26 (3), pp. 480-490. Date of Electronic Publication: 2016 Aug 06.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Autor: Dobroff AS; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., D'Angelo S; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Eckhardt BL; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Ferrara F; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Staquicini DI; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Cardó-Vila M; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Staquicini FI; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Nunes DN; International Research Center, A. C. Camargo Cancer Center, Sao Paulo 01508-010, Brazil., Kim K; MOGAM Biotechnology Institute, Yongin, Gyeonggi-do 16924, Korea., Driessen WHP; David H. Koch Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Hajitou A; Hammersmith Hospital Campus, Imperial College London, London W12 0NN, United Kingdom., Lomo LC; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM 87131., Barry M; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, NM 87131., Krishnamurthy S; Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Sahin A; Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Woodward WA; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Prossnitz ER; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Anderson RL; Department of Oncology, Sir Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC 3010, Australia., Dias-Neto E; International Research Center, A. C. Camargo Cancer Center, Sao Paulo 01508-010, Brazil.; Institute of Psychiatry, University of São Paulo Medical School, Sao Paulo 01060-970, Brazil., Brown-Glaberman UA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Royce ME; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Ueno NT; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Cristofanilli M; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611., Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030., Marchiò S; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131.; Candiolo Cancer Institute-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Turin 10060, Italy.; Department of Oncology, University of Turin, Candiolo, Turin 10060, Italy., Gelovani JG; Department of Biomedical Engineering, Wayne State University, Detroit, MI 48201., Sidman RL; Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215 richard_sidman@hms.harvard.edu rpasqual@salud.unm.edu warap@salud.unm.edu., Arap W; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131; richard_sidman@hms.harvard.edu rpasqual@salud.unm.edu warap@salud.unm.edu.; Division of Hematology/Oncology, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131., Pasqualini R; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131; richard_sidman@hms.harvard.edu rpasqual@salud.unm.edu warap@salud.unm.edu.; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131.

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2016 Nov 08; Vol. 113 (45), pp. 12780-12785. Date of Electronic Publication: 2016 Oct 24.

Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Autor: Lu J; College of Pharmacy, University of New Mexico, 2502 Marble NE, MSC09 5360, Albuquerque, NM 87131, United States., Hathaway HJ; Department of Cell Biology and Physiology, University of New Mexico, Albuquerque, NM 87131, United States; Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, United States., Royce ME; Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, United States; Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, United States., Prossnitz ER; Department of Cell Biology and Physiology, University of New Mexico, Albuquerque, NM 87131, United States; Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, United States., Miao Y; College of Pharmacy, University of New Mexico, 2502 Marble NE, MSC09 5360, Albuquerque, NM 87131, United States; Cancer Research and Treatment Center, University of New Mexico, Albuquerque, NM 87131, United States; Department of Dermatology, University of New Mexico, Albuquerque, NM 87131, United States. Electronic address: ymiao@salud.unm.edu.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2014 Feb 01; Vol. 24 (3), pp. 725-30. Date of Electronic Publication: 2014 Jan 06.